In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Immunocore, Ltd.

http://www.immunocore.com/

Latest From Immunocore, Ltd.

Finance Watch: Investors Remain Receptive To Biopharma, Health Care SPAC IPOs

Public Company Edition: 2020 started with two $200m-plus initial public offerings plus five health care-focused special purpose acquisition corporations IPOs. Also, a Pfizer initiative backs three public companies, Fate’s $432m offering led recent FOPOs and Biocon Biologics receives more investment. 

Financing Business Strategies

Immunocore Aims For $100m IPO After Immunotherapy Success

The UK biotech is set for a NASDAQ launch which could propel it to its first commercial launch by 2022.

BioPharmaceutical

Finance Watch: Biopharma VC Deals Hit New Record Of $27.4bn In 2020

Private Company Edition: Last year set a high bar for venture capital, but this year is starting strong. Recent VC mega-deals include $500m for EQRx and $230m-plus for Tessera Therapeutics. Also, BioGeneration Ventures closed a €140m ($170.2m) fund and NewAmsterdam raised a $196m series A.

Financing Innovation

Boehringer Explores ‘Dark Antigens’ With Enara In Potential $1bn Deal

Announcing its first big pharma deal, the Oxford-based biotech says there could be more to come – with mRNA pioneers also interested in shining a light on hidden drug targets.

Companies Commercial
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Drug Discovery Tools
      • ADMET
UsernamePublicRestriction

Register